Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis.
The effect of captopril on coxsackievirus B3 murine myocarditis was investigated. Thirty-two, 3-week-old mice were infected with coxsackievirus B3 on day 0 of the study, then randomized into a placebo group or a captopril group starting on day 3 of infection. On day 9 of infection, the mice were put to death. Hearts were weighed and processed for light microscopic examination. Heart weight was 125 +/- 19 mg in the control group versus 102 +/- 14 mg in the captopril group (p less than 0.0003). Amount of necrosis as a percentage of left ventricular section was 3.5% (2.0% to 7.5%) in the placebo group versus 2.0% (0.0% to 5.0%) in the captopril group (p less than 0.01). The amount of dystrophic calcification was 5.0% (0.0% to 27.5%) in the placebo group versus 1.3% (0.0% to 20.0%) in the captopril group (p less than 0.01). The extent of the histopathologic involvement by planimetry was 10.2% in the placebo group versus 5.4% in the captopril group (p = 0.052). We conclude that captopril is beneficial in decreasing left ventricular mass and the amount of myocardial necrosis and calcification in the short term in the murine myocarditis model.
Rezkalla
S
S
Department of Medicine, Harper Hospital, Detroit, Mich.
Kloner
R A
RA
Khatib
G
G
Khatib
R
R
D000208:Acute Disease; D000818:Animals; D002114:Calcinosis / Q000188:drug therapy / Q000473:pathology; D002216:Captopril / Q000627:therapeutic use*; D003384:Coxsackievirus Infections / Q000188:drug therapy* / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D029822:Enterovirus B, Human; D006321:Heart / Q000187:drug effects*; D006352:Heart Ventricles / Q000187:drug effects; D008168:Lung / Q000187:drug effects; D051379:Mice; D009205:Myocarditis / Q000188:drug therapy* / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D013997:Time Factors
D002216:Captopril